TNF Pharmaceuticals Inc. (NASDAQ:TNFA), ("TNF" or the "Company") today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days.

"We are pleased to have regained compliance with Nasdaq's listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. We will be updating shareholders on our progress in the weeks ahead," said Joshua Silverman, Executive Chairman.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: any setbacks in the expected benefits from the licensing agreement with LightSolver Ltd. or the performance or marketability of LightSolver's technology; unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact its liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; and the Company's ability to quickly and effectively respond to new technological developments. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917806538/en/

Investor Contact:

800-507-9010

tnfpharma.com/contact

TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement